Pradeep Natarajan, a distinguished geneticist and Director of Preventive Cardiology at Mass General Hospital, dives into groundbreaking advancements in heart disease prevention. He discusses innovative therapies, like small interfering RNAs, and their advantages over traditional treatments. The importance of APO-B in assessing cardiovascular risk, along with the implications of lipoprotein(a) and inflammation on heart health, are highlighted. Natarajan also emphasizes the need for integrating genetic insights and novel risk assessment methods into clinical practice.